CASIA OpenIR
Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging
Liang, Qian1,2,3; Kong, Lingxin1,2,3; Du, Yang1,2,3; Zhu, Xu4; Tian, Jie1,2,3,5,6
Source PublicationEXPERIMENTAL AND MOLECULAR MEDICINE
ISSN1226-3613
2019-07-08
Volume51Pages:11
Corresponding AuthorDu, Yang(yang.du@ia.ac.cn) ; Zhu, Xu(drzhuxu@163.com) ; Tian, Jie(jie.tian@ia.ac.cn)
AbstractHepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality worldwide. Sorafenib is the standard first-line treatment for advanced HCC, but its efficacy is limited. Apatinib is a small-molecule tyrosine kinas e inhibitor that has shown promising antitumor effects in gastric and non-small cell lung cancers in clinical trials, but there have been only a few studies reporting its anti-HCC effects in vitro and in HCC xenograft models. Hence, our present study systemically investigated and compared the antitumorigenic and antiangiogenic efficacy of apatinib and sorafenib in HCC in vitro and in vivo using multimodality molecular imaging, including bioluminescence imaging (BLI), bioluminescence tomography (BLT), fluorescence molecular imaging (FMI), and computed tomography angiography ( CTA). Moreover, the safety and side effects of the two drugs were systemically evaluated. We found that apatinib showed a comparable therapeutic efficacy to sorafenib for the inhibition of HCC. The drug safety evaluation revealed that both of these drugs caused hypertension and mild liver and kidney damage. Sorafenib caused diarrhea, rash, and weight loss in mice, but these effects were not observed in mice treated with apatinib. In conclusion, apatinib has similar antitumorigenic and antiangiogenic efficacy as sorafenib in HCC with less toxicity. These findings may provide preclinical evidence supporting the potential application of apatinib for the treatment of HCC patients.
DOI10.1038/s12276-019-0274-7
WOS KeywordHEPATOCELLULAR-CARCINOMA ; THERAPY ; ANGIOGENESIS ; TOMOGRAPHY ; MODELS ; TUMORS
Indexed BySCI
Language英语
Funding ProjectNational Key Research and Development Plan of China[2017YFA0205200] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81227901] ; Strategic Priority Research Program from Chinese Academy of Sciences[XDB02060010] ; International Innovation Team of CAS[20140491524] ; Beijing Municipal Science and Technology Commission[Z161100002616022]
Funding OrganizationNational Key Research and Development Plan of China ; National Natural Science Foundation of China ; Strategic Priority Research Program from Chinese Academy of Sciences ; International Innovation Team of CAS ; Beijing Municipal Science and Technology Commission
WOS Research AreaBiochemistry & Molecular Biology ; Research & Experimental Medicine
WOS SubjectBiochemistry & Molecular Biology ; Medicine, Research & Experimental
WOS IDWOS:000474511300002
PublisherNATURE PUBLISHING GROUP
Citation statistics
Cited Times:1[WOS]   [WOS Record]     [Related Records in WOS]
Document Type期刊论文
Identifierhttp://ir.ia.ac.cn/handle/173211/26901
Collection中国科学院自动化研究所
Corresponding AuthorDu, Yang; Zhu, Xu; Tian, Jie
Affiliation1.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, State Key Lab Management & Control Complex Syst, Beijing 100190, Peoples R China
2.Univ Chinese Acad Sci, Beijing 100080, Peoples R China
3.Beijing Key Lab Mol Imaging, Beijing 100190, Peoples R China
4.Peking Univ, Dept Intervent Therapy, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Sch Oncol, 52 Fucheng Rd, Beijing 100142, Peoples R China
5.Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Sch Med, Beijing 100191, Peoples R China
6.Xidian Univ, Engn Res Ctr Mol & Neuro Imaging, Sch Life Sci & Technol, Minist Educ, Xian 710126, Shaanxi, Peoples R China
First Author AffilicationInstitute of Automation, Chinese Academy of Sciences;  Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing 100190, Peoples R China
Corresponding Author AffilicationInstitute of Automation, Chinese Academy of Sciences;  Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing 100190, Peoples R China
Recommended Citation
GB/T 7714
Liang, Qian,Kong, Lingxin,Du, Yang,et al. Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging[J]. EXPERIMENTAL AND MOLECULAR MEDICINE,2019,51:11.
APA Liang, Qian,Kong, Lingxin,Du, Yang,Zhu, Xu,&Tian, Jie.(2019).Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging.EXPERIMENTAL AND MOLECULAR MEDICINE,51,11.
MLA Liang, Qian,et al."Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging".EXPERIMENTAL AND MOLECULAR MEDICINE 51(2019):11.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Liang, Qian]'s Articles
[Kong, Lingxin]'s Articles
[Du, Yang]'s Articles
Baidu academic
Similar articles in Baidu academic
[Liang, Qian]'s Articles
[Kong, Lingxin]'s Articles
[Du, Yang]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Liang, Qian]'s Articles
[Kong, Lingxin]'s Articles
[Du, Yang]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.